Pfizer Inc., one of the world’s leading pharmaceutical companies, its performance of the pharmaceutical industry is currently under the spotlight as the market leader in the area, especially in light of the impact of the COVID-19 epidemic starting at the end of 2019. Based on the financial reports and performance status of Pfizer Inc., and its competitors’(AstraZeneca, Merck Pharmaceuticals, and AbbVie) performances in the last two years, important changes in accounting policy, performance evaluation, and overall future strategic development of Pfizer are analyzed and evaluated. As a company that keeps paying more attention to biopharmaceuticals and acquisition, analysis regarding R&D, restructuring charges and risk management will be highlighted. At the same time, comparing Pfizer with the other three companies, analyzing their strengths and weaknesses, and forecasting Pfizer's 2023 development and total stock market capitalization is of great importance. For Pfizer, 2023 will be a turning point and critical year that will determine future product development and total sales performance in the 2023 financial year.